To the full analysis
Shenzhen Mindray Bio-Medical Electronics stock: growth
300760.SZShenzhen Mindray Bio-Medical Electronics reported $4.99B in revenue for fiscal 2025, down 9.4% on the prior year, up 9.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
14.1%
per year from 2014 to 2025, per share 11.3%
Earnings (Annual rate)
17.7%
per year from 2014 to 2025, per share 14.8%
Free cash flow (Annual rate)
19.4%
per year from 2014 to 2025, per share 16.5%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2014 | |
|---|---|---|---|
| Revenue | 9.6% | 15.3% | 14.1% |
| Revenue per share | 9.7% | 12.3% | 11.3% |
| Earnings | 4.1% | 24.5% | 17.7% |
| Earnings per share | 4.1% | 21.2% | 14.8% |
| Free cash flow | 1.1% | 19.0% | 19.4% |
| Free cash flow per share | 1.1% | 15.8% | 16.5% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2014 | $1.18B | $203.9M | $172.91M |
| 2015 | $1.2B | $136.45M | $214.22M |
| 2016 | $1.35B | $240.01M | $393.8M |
| 2017 | $1.68B | $388.28M | $424.94M |
| 2018 | $2.06B | $557.75M | $503.33M |
| 2019 | $2.48B | $701.93M | $591.6M |
| 2020 | $3.15B | $998.41M | $1.15B |
| 2021 | $3.79B | $1.2B | $1.14B |
| 2022 | $4.55B | $1.44B | $1.53B |
| 2023 | $5.24B | $1.74B | $1.26B |
| 2024 | $5.51B | $1.75B | $1.57B |
| 2025 | $4.99B | $1.22B | $1.22B |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 2 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.